Shenzhen Kangtai Biological Products Co., Ltd.

Shenzhen Stock Exchange 300601.SZ

Shenzhen Kangtai Biological Products Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -58.88 M

Shenzhen Kangtai Biological Products Co., Ltd. Net Cash Used Provided By Financing Activities is USD -58.88 M for the year ending December 31, 2023, a 12.59% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Shenzhen Kangtai Biological Products Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -67.37 M, a -117.46% change year over year.
Shenzhen Kangtai Biological Products Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 385.92 M, a -33.34% change year over year.
Shenzhen Kangtai Biological Products Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 578.90 M, a 1,877.98% change year over year.
Shenzhen Kangtai Biological Products Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD -32.56 M, a -167.49% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Shenzhen Stock Exchange: 300601.SZ

Shenzhen Kangtai Biological Products Co., Ltd.

CEO	Ms. Hui Zhou
IPO Date	Feb. 8, 2017
Location	China
Headquarters	Science and Technology Park
Employees	1,902
Sector	Healthcare
Industries Vaccines

Description

Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined with live attenuated vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, and HIB conjugate vaccine. It has an agreement between YTB and Yong Tai Berhad in relation to the development and commercialization of Covid-19 inactivated vaccine in Malaysia. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.

Key trends

Past 5 years